Full Press Release Details
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 8:10 am ET in New York.
A live webcast of the fireside chat can be accessed under “Events & Presentations” on the Company’s website atwww.verastem.com. A replay of the webcasts will be archived on the website for approximately 90 days following the presentation.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Verastem marketsAVMAPKI® FAKZYNJA® CO-PACKin the U.S. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, includingRAF/MEK inhibition,FAK inhibition, andKRAS G12D inhibition. For more information, please visitwww.verastem.comand follow us onLinkedIn.